A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

NCT06709040 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Growth Hormone Deficiency
Neoplasms
Diabetes Mellitus Type 2

Interventions

DRUG: Somapacitan

Sponsor

Novo Nordisk A/S